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Abstract
Background—Dietary linoleic acid (LA, 18:2n-6) lowering in rats reduces n-6 polyunsaturated
fatty acid (PUFA) plasma concentrations and increases n-3 PUFA (eicosapentaenoic (EPA) and
docosahexaenoic acid (DHA)) concentrations.
Objective—To evaluate the extent to which 12 weeks of dietary n-6 PUFA lowering, with or
without increased dietary n-3 PUFAs, change unesterified and esterified plasma n-6 and n-3
PUFA concentrations in subjects with chronic headache.
Design—Secondary analysis of a randomized trial. Subjects with chronic headache were
randomized for 12 weeks to: (1) average n-3, low n-6 (L6) diet; or (2) high n-3, low n-6 LA (H3-
L6) diet. Esterified and unesterified plasma fatty acids were quantified at baseline (0 weeks) and
after 12 weeks on a diet.
Results—Compared to baseline, the L6 diet reduced esterified plasma LA and increased
esterified n-3 PUFA concentrations (nmol/ml), but did not significantly change plasma
*Corresponding author. Ameer Y. Taha, PhD, 9000 Rockville Pike, Building 9, 1S-126, BPMS, National Institute on Aging, National
Institutes of Health, Bethesda, MD 20892, ameer.taha@nih.gov, Phone: 301-394-8393, Fax: 301-402-0074.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Prostaglandins Leukot Essent Fatty Acids. Author manuscript; available in PMC 2015 May 01.
Published in final edited form as:






















arachidonic acid (AA, 20:4n-6) concentration. In addition, unesterified EPA concentration was
increased significantly among unesterified fatty acids. The H3-L6 diet decreased esterified LA and
AA concentrations, and produced more marked increases in esterified and unesterified n-3 PUFA
concentrations.
Conclusion—Dietary n-6 PUFA lowering for 12 weeks significantly reduces LA and increases
n-3 PUFA concentrations in plasma, without altering plasma AA concentration. A concurrent
increase in dietary n-3 PUFA for 12 weeks further increases n-3 PUFA plasma concentrations, but
also reduces AA.
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Arachidonic acid; omega-6 (n-6); omega-3 (n-3); polyunsaturated fatty acids; esterified;
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1. Introduction
Linoleic acid (LA, 18:2n-6) is a major constituent of the North American diet, accounting
for approximately 7% of daily caloric intake and 20% of total dietary fatty acids (~16 g LA /
day) [1]. This intake is more than three-fold higher than the historic norm of 2%, owing
mainly to the increased consumption of seed oils containing 20–54% LA of total fatty acids
[1]. The biochemical and health implications of this change are not fully understood.
The mammalian liver can convert LA to longer chain n-6 PUFAs, particularly arachidonic
acid (AA, 20:4n-6), by elongation-desaturation via Δ5 and Δ6 desaturases and elongases-2
and -5. LA competes with alpha-linolenic acid (α-LNA, 18:3n-3) for elongation-
desaturation enzymes that convert α-LNA to longer chain n-3 PUFAs including
eicosapentaenoic acid (EPA, 20:5 n-3), n-3 docosapentaenoic acid (n-3 DPA 22:5n-3) and
docosahexaenoic acid (DHA, 22:6n-3) [2, 3], which have several putative health benefits [4–
6]. LA and AA are precursors to bioactive LA oxidation products [7] and eicosanoids [8],
respectively, which have been implicated in pathological conditions such as non-alcoholic
steatohepatitis, Alzheimer disease and asthma [9–11]. By contrast, n-3 EPA, DPA and DHA
can be converted into anti-inflammatory and pro-resolving lipid mediators [12, 5, 13, 14].
In rodents, dietary LA lowering has been shown to reduce the absolute concentration of AA
(nmol per ml plasma or g tissue), and to increase EPA, DPA and DHA concentrations in
plasma and numerous tissues [15, 2, 16, 17]. However, comparatively few human trials have
evaluated the biochemical effects of lowering dietary LA. To our knowledge, there are no
human data indicating that altering dietary LA changes circulating AA concentrations [18–
20]. By contrast, dietary LA lowering in humans was reported to increase α-LNA
conversion to EPA and DHA [21], to increase the EPA and DHA content of erythrocytes
[19] and to increase EPA in plasma phospholipids [18]. In these human studies, data were
expressed as percent composition (% of total fatty acids), which may not necessarily reflect
changes in absolute concentrations because a change in the concentration of one fatty acid
can reflect a change in the opposite direction of another [22, 23]. The effects of dietary n-6
PUFA lowering in humans on absolute n-3 and n-6 PUFA concentrations have not been
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reported for unesterified and esterified (phospholipids, triglycerides, cholesteryl esters)
plasma lipid fractions.
We recently reported that the combination of increasing dietary n- 3 fatty acids with
concurrent reduction in n-6 LA produced statistically significant, clinically relevant
improvements in headache frequency, intensity and quality of life in chronic headache
patients [24], a condition with reported elevations of AA-derived mediators in blood and
saliva [25, 24, 26]. Blood collected from this trial provides a unique opportunity to evaluate
the effects of targeted alterations of dietary n-3 and n-6 fatty acids on plasma esterified and
unesterified fatty acid concentrations [19, 24], which could be used as biomarkers to relate
efficacy in dietary treatment effects.
In the present study, we sought to evaluate the effects of dietary n-6 lowering with or
without concurrent increases in dietary n-3 PUFA on unesterified and esterified plasma lipid
fractions, using plasma samples from a completed dietary trial in patients with chronic
headaches [19, 24]. We tested the following hypotheses: (1) an average n-3, low n-6 (L6)
dietary intervention would increase n-3 PUFA and decrease n-6 AA absolute concentrations
in esterified and unesterified plasma lipid pools; and (2) a high n-3, low n-6 LA (H3-L6)
dietary intervention would produce significantly greater increases in circulating n-3 PUFA
concentrations and reductions in AA concentrations.
2. Materials and Methods
2.1. Patients and dietary methods
A detailed description of the dietary methods and procedures of the main trial have been
published [19, 24, 27]. The trial was conducted at The University of North Carolina at
Chapel Hill (UNC) from April 2009 to November 2011. Subjects signed informed consent
prior to participation. Trial procedures were approved by the UNC Institutional Review
Board. This trial is registered under ClinicalTrials.gov (NCT01157208). In brief, sixty-seven
subjects with chronic headaches were randomized to either a low n-6 PUFA (L6) diet or a
high n-3 plus low n-6 PUFA (H3-L6) to be maintained for 12-weeks. Nutrient compositions
of the two interventions are shown in Table 1. The interventions were designed to be equally
credible and to provide equivalent: (1) amounts of study foods; (2) macronutrient and caloric
intake; (3) interactions with the study investigators and dietitian; and (4) intensity and
breadth of dietary advice and intervention materials [19]. A registered dietitian provided
intensive counseling at randomization and at 2-week intervals. Foods meeting nutrient
targets were provided to participants for two meals and two snacks per day. Detailed
intervention-specific web-based materials were also provided to reinforce dietitian advice
and complement the study food provision. To assess nutrient intakes six unannounced
telephone-administered 24-hour recalls were administered for each participant– three during
the baseline phase and three in the final four weeks of the intervention phase–as previously
described [19].
Fifty-six of the 67 randomized participants completed the 12-week intervention phase, with
55 providing pre- and post-intervention plasma samples (28 in the L6 group and 27 in the
H3-L6 group). Baseline demographics and clinical characteristics were comparable in the
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two groups (Table 2); 87% of randomized subjects were female. At baseline, participants
averaged 23 headache days per month and 10 headache hours per day, and reported taking
an average of six different headache-related medications per subject.
2.2. Sample collection
Fasting whole blood, drawn at baseline and again after 12 weeks of dietary intervention, was
collected into ethylenediaminetetraacetic acid (EDTA) tubes. Samples were immediately
centrifuged at 2000g for 15 min at room temperature, and plasma aliquots were stored in a
−80°C freezer until analysis. Sample preparation and analyses were performed by
investigators who were blinded to the study protocol and clinical data.
2.3. Analysis of plasma esterified and unesterified fatty acids
Total lipids were extracted from 200 µl of plasma in 3 ml of 2:1 chloroform / methanol
following the addition of unesterified heptadecaenoic acid (17:0) as an internal standard
(0.14 nmol/µl) for unesterified fatty acids. KCl (0.5 M, 0.75 ml) was then added to separate
the aqueous phase. The bottom chloroform layer was separated and re-extracted with 2 ml
chloroform. The pooled chloroform extracts containing total lipids were dried down and
separated into neutral lipid subclasses (cholesteryl esters, triacylglycerol, unesterified fatty
acids, and total phospholipids) using silica gel-60 thin layer chromatography plates (EM
Separation Technologies, Gibbstown, NJ, USA), in a heptane: diethylether: glacial acetic
acid (60:40:3, by vol) solvent system [28]. Authentic standards of neutral lipids and
phospholipid classes were run on separate lanes on the plates to identify lipid bands under
ultraviolet light, after spraying with 0.03% 6-p-toluidine-2-naphthalene sulfonic acid in 50
mM Tris-HCl buffer (pH 7.4) (w/v). The bands were scraped into test tubes and methylated
with 1% H2SO4 in methanol for 3 h at 70°C [29]. Before methylation, di-17:0 PC was added
to each tube as an internal standard for phospholipids, triglycerides and cholesteryl esters.
The prepared fatty acid methyl esters (FAMEs) were analyzed by a gas-chromatography
system (6890N, Agilent Technologies, Palo Alto, CA, USA) equipped with an SPTM-2330
fused silica capillary column (30 m × 0.25 mm i.d., 0.25 µm film thickness) (Supelco,
Bellefonte, PA, USA) and a flame ionization detector as previously described [30]. Fatty
acid concentrations were calculated by proportional comparison of peak areas of samples to
the area of the 17:0 internal standard.
2.4. Data Analysis
Non-parametric analyses were employed due to the presence of non-normal distributions.
Pre-to-post intervention comparisons were tested with the Wilcoxon Signed-Rank test for
matched pairs. A Mann Whitney U test was used to compare differences in fatty acid
concentrations between the two groups at baseline and at 12 weeks. Statistical significance
was accepted at P ≤ 0.05.
3. Results
3.1. Baseline fatty acid concentrations
As shown in Tables 3 to 6, absolute baseline fatty acid concentrations in plasma
phospholipids, triglycerides, cholesteryl esters and unesterified fatty acids did not differ
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significantly between the groups (P > 0.05 by Mann-Whitney U test). Baseline absolute
concentrations for esterified and unesterified fatty acids are comparable to a previous report
in humans exposed to similar North American intakes of LA [31]. The percent composition
in the various lipid pools are presented in Supplementary Tables 1 to 4, and are comparable
to values in other studies [32, 33].
3.2. Phospholipid fatty acid concentrations
Table 3 shows median phospholipid fatty acid concentrations. Compared to baseline, dietary
n-6 lowering (L6 group) decreased absolute concentrations (nmol / ml) of LA (12%) and n-6
DPA (22:5n-6; 26%), and increased concentrations of oleic acid (18:1n-9; 9%), α-LNA
(20%), EPA (33%), n-3 DPA (22:5n-3; 21%) and DHA (9%). In the H3-L6 group, absolute
concentrations of LA, AA, docosatetraenoic acid (DTA, 22:4n-6) and n-6 DPA were
reduced significantly compared to baseline by 19%, 20%, 28% and 50%, respectively,
whereas α-LNA, EPA, n-3 DPA and DHA concentrations were increased by 39%, 271%,
25% and 112%, respectively. The changes in LA, AA, EPA, DTA, n-6 DPA and DHA
concentrations relative to baseline were higher in the H3-L6 than the L6 group, as evidenced
by the statistically significant differences between the L6 and H3-L6 groups at 12 weeks (P
< 0.05 by Mann-Whitney U test, final column in Table 3).
3.3. Triglyceride fatty acid concentrations
Within triglycerides, only the LA concentration was changed significantly (−29%) compared
to baseline in the L6 group (Table 4). The H3-L6 intervention produced a comparable
reduction in triglyceride LA concentration (−24%), with concurrent reductions in n-6 DPA
and AA (−25 to −29%), and increased α-LNA, EPA, n-3 DPA and DHA concentrations
(+57 to 216%). At 12 weeks, EPA and DHA concentrations in the H3-L6 group were
significantly higher than in the L6 group (P < 0.05 by Mann-Whitney U test, final column in
Table 4).
3.4. Cholesteryl ester fatty acid concentrations
In cholesteryl ester, n-6 lowering for 12 weeks increased palmitic acid, oleic acid, α-LNA,
EPA and DHA concentrations by 7–45%, and decreased LA concentration by 9% compared
to baseline (Table 5). The H3-L6 intervention significantly reduced AA by 13% (but not
LA) and increased palmitic acid, oleic acid, α-LNA, EPA and DHA concentrations by 21%,
90%, 365% and 99%, respectively (P < 0.001), compared to baseline. At 12 weeks, α-LNA
and EPA were significantly higher in the H3-L6 compared to the L6 group (P < 0.05 by
Mann-Whitney U test, final column in Table 5).
3.5. Unesterified fatty acid concentrations
Compared to baseline, the EPA concentration within unesterified fatty acids was
significantly increased (+30%) in the L6 group at 12 weeks (Table 6). This increase was
much higher in the H3-L6 group (+199%; P < 0.001). n-3 DPA and DHA were significantly
higher by 19% and 221%, respectively, in the H3-L6 group at 12 weeks compared to
baseline (P<0.01). Statistical comparison of the medians at 12 weeks by the Mann-Whitney
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U test indicated that EPA and DHA were significantly higher in the H3-L6 compared to the
L6 group.
4. Discussion
Dietary n-6 PUFA lowering (the L6 intervention) for 12 weeks did not significantly alter the
AA concentration (nmol/ml) in any esterified or unesterified plasma lipid fraction of
headache patients, but did increase the n-3 PUFA concentration of both esterified and
unesterified plasma lipids. By contrast, dietary LA lowering with concurrent increase in
dietary EPA and DHA (the H3-L6 intervention) significantly reduced plasma AA
concentration, and produced significantly greater increases in n-3 PUFA concentrations in
esterified and unesterified plasma lipids.
4.1. The L6 intervention
Findings in the L6 group are consistent with previous reports showing that dietary LA
lowering for 8–12 weeks in humans without concurrent increases in dietary n-3 PUFA
significantly increased n-3 EPA, DPA and DHA concentrations in various circulating lipid
pools [34, 18, 24]. Increases in plasma esterified EPA, n-3 DPA and DHA concentrations
produced by the L6 intervention could reflect increased hepatic synthesis-secretion from α-
LNA, because dietary LA lowering might enhance the elongation-desaturation of α-LNA by
reducing LA substrate availability and subsequent competition between LA and α-LNA for
liver conversion into their respective longer-chain PUFAs [35]. This interpretation is
consistent with evidence of increased hepatic desaturase and elongase transcription [35] and
increased plasma and tissue EPA, n-3 DPA and DHA concentrations in rats fed a low LA
diet [36, 16]. Since dietary LA also competes with n-3 EPA and DHA for esterification
within liver phospholipids [37], reduced competition for esterification also may have
contributed to the observed increase in n-3 PUFA concentration of phospholipids,
triglycerides and cholesteryl esters in the L6 group.
The failure of the L6 intervention to significantly reduce the AA concentration in any
plasma lipid pool is consistent with our erythrocyte assays from the same trial showing no
change in AA percent composition [19, 24]. Interestingly, this L6 intervention produced
significant reductions in the absolute concentrations of DTA and n-6 DPA (products of AA
elongation / desaturation) in plasma phospholipids, despite the lack of reduction in AA. This
discrepancy suggests that a diet-induced reduction in AA synthesis may be offset by
homeostatic mechanisms that maintain AA concentrations, such as increased adipose
mobilization of AA by hormone-sensitive lipase [38] or reduced metabolic conversion of
AA into bioactive mediators [24]. Reduced AA metabolism is consistent with our report that
the L6 intervention significantly reduced several bioactive hydroxy-eicosatetraenoic acid
(HETE) derivatives of AA in plasma, without altering plasma or erythrocyte AA content
[19, 24].
Plasma reductions in esterified AA concentration in the L6 group might become evident
during a study sufficiently long to reduce adipose tissue AA stores, which may take years in
view of 1–2 year fatty acid half-lives in human adipose tissue [39]. The disconnect between
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diet-induced changes in AA and AA-derived bioactive mediators suggests that simply
measuring fatty acid concentrations may not adequately reflect metabolic state.
4.2. The H3-L6 intervention
The more marked increase (>10-fold) in esterified n-3 PUFAs in the H3-L6 diet compared
to the L6 diet group was likely due to competition between dietary (preformed) n-3 EPA and
DHA and other n-6 PUFAs for esterification. Since hepatic synthesis of EPA and DHA from
α-LNA can be inhibited by dietary EPA and /or DHA supplementation in humans and
rodents [3, 40, 41], the contribution of α-LNA to the increased long-chain plasma n-3 PUFA
concentrations in the H3-L6 group likely was small compared to that of preformed dietary
EPA and DHA. Consistent with this interpretation, clinical trials of α-LNA supplementation
for up to one year did not change plasma DHA concentrations [42, 43].
The decrease in AA concentration in plasma phospholipid, triglyceride and cholesteryl
esters in the H3-L6 group compared to the L6 group likely reflects reduced AA synthesis-
secretion, since the consumption of EPA and DHA likely reduces the activity of elongase
and desaturase enzymes involved in both AA and EPA synthesis [3, 41]. The observed
reduction in AA concentration may also reflect competition of ingested EPA and DHA with
endogenous AA for incorporation into phospholipids, triglycerides or cholesteryl esters
within liver [44].
Adipose tissue unesterified fatty acid release and circulating esterified fatty acids secreted
by the liver are the two principle sources of circulating unesterified fatty acids, the species
that are preferentially incorporated into the brain [45, 46]. In this study, unesterified plasma
EPA was increased in the L6 group, and unesterified plasma EPA, n-3 DPA and DHA were
increased in the H3-L6 group, consistent with the increases in their respective esterified
concentrations. By contrast, unesterified n-6 PUFA concentrations did not change in either
group, despite being reduced within their esterified pools. LA presently accounts for 14–
18% of total adipose fatty acids in the North American population [47], compared to about
6% in 1961 [48, 49], suggesting that a prolonged period of LA-lowering may be necessary
to sufficiently reduce adipose stores and decrease LA in the unesterified fatty acid pool.
Clearly, a different and more rapid homeostatic state was attained for n-3 PUFAs, which are
much less abundant in adipose tissue (< 2%) compared to n-6 PUFAs (~20%) [47].
4.3. Potential implications for brain PUFA metabolism and neuroinflammation
In rats, dietary LA lowering from 3.5% to 0.3% energy for 15 weeks increased n-3 PUFA
concentrations and decreased plasma unesterified and esterified LA and AA concentrations
[17]. These changes were accompanied by decreased expression and activity of AA-
releasing calcium-dependent phospholipase A2 (cPLA2) IVA and AA-metabolizing
cyclooxygenase-2 (COX-2), and increased expression and activity of DHA-releasing
calcium-independent phospholipase A2 (iPLA2 VIA) [50]. Since cPLA2 and COX-2 are
upregulated during neuroinflammation, and increased iPLA2 VIA reflects increased DHA
metabolism into bioactive pro-resolving metabolites, it is possible that that the H3-L6
intervention (and to a lesser extent the L6 intervention) would attenuate neuroinflammation.
This may explain the efficacy of the H3-L6 diet in reducing headache frequency in patients
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with chronic migraine [24]. Future trials are needed to determine the efficacy of n-6 PUFA
lowering and n-3 supplementation on brain PUFA metabolism and neuroinflammation in
humans.
4.4. Limitations
The present trial was conducted in a population with high n-6 LA and low n-3 EPA+DHA
consumption at baseline. The magnitudes of changes in plasma lipids may differ in
populations with different dietary characteristics. Since this study was conducted in a
predominantly female patient population with chronic headaches, the observed biochemical
changes are not necessarily generalizable to men or neurologically healthy individuals.
4.5. Conclusion
In conclusion, 12 weeks of dietary n-6 lowering increased concentrations of n-3 PUFAs in
plasma esterified and unesterified lipids, and a combination of dietary LA lowering with
concurrent increases in EPA and DHA further increased circulating n-3 PUFA levels and
reduced esterified AA and other n-6 PUFA concentrations in a patient population with
chronic headaches.
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Table 2





Age, y, mean (SD) 41 (13.4) 42 (11.1)
Female, n (%) 28 (84.8) 30 (88.2)
White race, n (%) 28 (84.8) 30 (88.1)
Married, n (%) 19 (57.6) 19 (55.9)
Education, n (%)
  High school or college 20 (60.6) 19 (59.3)
  Master's degree or higher 13 (40.6) 13 (39.4)
Employment, n (%)
  Employed/student 26 (78.8) 23 (69.7)
  Retired/Caretaker 3 (9.1) 3 (9.1)
  Disabled/unemployed 4 (12.1) 7 (20.0)
Headache days per month, mean (SD) 23.3 (20.9, 25.8) 23.2 (20.2, 25.8)
Headache hours per day, mean (SD) 10.2 (8.4, 12.3) 9.8 (8.1, 11.8)
Number of different headache-related medications, mean (SD) 6.4 (3.4) 5.6 (3.3)
Adapted from reference [24]., number of subjects;%, proportion of subjects; SD, standard deviation.
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